Overview

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)
Phase:
Phase 1
Details
Lead Sponsor:
Life Molecular Imaging GmbH